HDAC1 and acute lymphoblastic leukemia: HDAC1/2 inhibitors trigger apoptosis in acute lymphoblastic leukemia, while HDAC3 inhibitors are more effective in T‐cell lymphoma cell lines, suggesting that selectively targeting HDAC1/2/3 might be beneficial in certain disorders [23].